PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
11.35%
Some net income increase while AVXL is negative at -9.20%. John Neff would see a short-term edge over the struggling competitor.
1.31%
D&A growth of 1.31% while AVXL is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
No Data
No Data available this quarter, please select a different quarter.
-12.55%
Both cut yoy SBC, with AVXL at -8.41%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
-199.74%
Negative yoy working capital usage while AVXL is 61.20%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
AP growth of 100.00% while AVXL is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might matter for short-term liquidity if expansions are large.
-382.74%
Negative yoy usage while AVXL is 61.20%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-25.35%
Negative yoy while AVXL is 24.69%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
2.31%
Some CFO growth while AVXL is negative at -4.12%. John Neff would note a short-term liquidity lead over the competitor.
83.69%
CapEx growth of 83.69% while AVXL is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
83.69%
We expand invests by 83.69% while AVXL is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
No Data
No Data available this quarter, please select a different quarter.
3875.79%
Stock issuance far above AVXL's 54.12%. Michael Burry flags a significant dilution risk vs. competitor’s approach unless ROI is very high.
No Data
No Data available this quarter, please select a different quarter.